USFDA approved first generic of Advair Diskus
The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the... Read More
USFDA accepted the Roche’s sBLA for Tecentriq (atezolizumab) in combination with Abraxane
Posted on30 Jan 2019
Comments0
US Food and Drug Administration (FDA) has accepted the Roche’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane®... Read More
USFDA approved Imbruvica in combo with obinutuzumab for adult patients with previously untreated CLL/SLL
AbbVie, a research-based global biopharmaceutical company, announced that the US Food and Drug Administration (FDA) approved the use of Imbruvica (ibrutinib) in... Read More
Pfizer’s launches awareness and advocacy program on antibiotic resistance
Posted on28 Jan 2019
Comments0
ABOUT ICMR PFIZER CENTRE FOR AMR RESEARCH & EDUCATION In February 2018, the Indian Council of Medical Research (ICMR) and Pfizer signed... Read More
What is an “audit trail”?
Audit trail means a secure, computer-generated, time-stamped electronic record that allows for reconstruction of the course of events relating to the creation,... Read More
US FDA approval of 0.5 ml dose of Sanofi’s Fluzone Quadrivalent in children as young as 6 months of age
The US Food and Drug Administration (FDA) has approved the use of the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) to... Read More
Abbott to acquire medical device company, Cephea Valve Technologies
Abbott, a global healthcare company, announced that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical... Read More
Sandoz introduces Symjepi 0.3 mg injection in US market to treat allergic reactions
Sandoz Inc, a Novartis division, announced the US market introduction of Symjepi (epinephrine) 0.3 mg injection for the emergency treatment of allergic... Read More
US FDA accepts Roche’s sBLA for Tecentriq in combo with Abraxane and carboplatin to treat metastatic NSCLC
Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Tecentriq (atezolizumab)... Read More